| Glycaemic control with liraglutide: the phase 3 trial programme. | |
| | |
MedLine Citation:
|
PMID: 20887301 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: To review the efficacy and safety of liraglutide from the phase 3 trials, focusing primarily on glycaemic control. KEY FINDINGS: Liraglutide was shown to reduce glycated haemoglobin (HbA(1c) ) levels by up to 1.5% from baseline, significantly more than the comparators sitagliptin (-0.9%), glimepiride (-0.5%), rosiglitazone (-0.4%), insulin glargine (-1.1%) and exenatide (-0.8%). Both fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) levels were shown to be significantly reduced from baseline [up to -2.4 mmol/l (-43.2 mg/dl) and -2.7 mmol/l (-48.6 mg/dl) for FPG and PPG in the liraglutide 1.8 mg group, respectively]. Changes in HbA(1c) , FPG and PPG levels were sustained for the duration of the studies (up to 52 weeks). The glycaemic control offered by liraglutide was not associated with an increased rate of minor hypoglycaemic events compared with comparator treatments, with rates significantly lower than those of glimepiride and exenatide. Major hypoglycaemic events were rare and only occurred in combination with a sulfonylurea. Nausea was the most frequent adverse event, but subsided within the first few weeks. CONCLUSIONS: Liraglutide has been shown to offer effective glycaemic control for patients with type 2 diabetes and is appropriate for use across the conventional continuum of care. Despite the sustained reductions in HbA(1c) , FPG and PPG levels achieved with liraglutide, rates of minor hypoglycaemia were generally low, although the risk increased when combined with a sulfonylurea. Liraglutide is therefore a promising new option for the treatment of type 2 diabetes. |
| | |
Authors:
|
P Raskin; P F Mora |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: International journal of clinical practice. Supplement Volume: - ISSN: 1368-504X ISO Abbreviation: Int J Clin Pract Suppl Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-04 Completed Date: 2011-04-27 Revised Date: 2011-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9712380 Medline TA: Int J Clin Pract Suppl Country: England |
Other Details:
|
Languages: eng Pagination: 21-7 Citation Subset: IM |
Copyright Information:
|
© 2010 Blackwell Publishing Ltd. |
Affiliation:
|
University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA. Philip.Raskin@utsouthwestern.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Blood Glucose
/
drug effects,
metabolism Clinical Trials, Phase III as Topic Diabetes Mellitus, Type 2 / drug therapy*, metabolism Drug Therapy, Combination / adverse effects, methods Glucagon-Like Peptide 1 / administration & dosage, adverse effects, analogs & derivatives*, pharmacokinetics Hemoglobin A, Glycosylated / metabolism Humans Hypoglycemia / chemically induced Hypoglycemic Agents / administration & dosage, adverse effects, pharmacokinetics Nausea / chemically induced |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/liraglutide; 89750-14-1/Glucagon-Like Peptide 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Early clinical studies with liraglutide.
Next Document: Liraglutide: effects beyond glycaemic control in diabetes treatment.